Phase 1 First-in-Human Single-and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections

Phase 1 First-in-Human Single-and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections